Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


UK’s Leading Specialist HIV Diagnostics Company secures £675,000 for European Roll-Out
Delphic acquires HIV therapeutic drug monitoring service from The University of Liverpool


Delphic Europe Ltd, the UK’s leading provider of specialist diagnostics products and services for HIV clinics, has raised £675,000 from MMC Ventures, who led the funding round, and The Capital Fund. Delphic will use the new funds to expand its unique ‘one-stop-shop’ HIV diagnostics service, which includes viral resistance testing, therapeutic drug monitoring and genetic screening, to HIV centres and sexual health clinics across Europe.

Delphic has further strengthened its position by acquiring the world-leading clinical therapeutic drug monitoring service developed by the Liverpool HIV Pharmacology Group. This latest acquisition builds upon Delphic’s recent purchase of the genetics laboratory Genovar Bioscience Ltd.

With the advent of combination antiretroviral drug therapy, HIV has become a chronic condition requiring lifelong treatment and routine diagnostic intervention. HIV diagnostics are, however, supplied by a fragmented system of hospital laboratories and generalist providers with turnaround times and reporting formats meeting the needs of the laboratory rather than the clinician.

Tim Leaver, Founder and Managing Director of Delphic, said:
“Diagnostic monitoring is now an integral part of the treatment of HIV. The conjunction of virology, pharmacology and genetic screening has allowed individualised care to become the ‘standard of care’ in HIV treatment, ensuring that patients are on the right drugs and achieve the right concentration of those drugs. Delphic provides a clinician-focussed service, supplying a suite of coordinated diagnostic tests to rapid turnaround times. We are also expanding into routine testing, such as viral load testing for HIV and hepatitis, and are developing a new bioinformatics-based product with the support of an advisory panel of world HIV key opinion leaders.”

Founded in 2001 by Tim Leaver, Delphic’s board includes world experts and key opinion leaders in HIV, Professor David Back and Dr Saye Khoo (University of Liverpool) and Dr Anton Pozniak (Chelsea and Westminster Hospital).

Mr Leaver continued:
“Delphic is a revenue-generating business and is now ready to roll out its proven business model into the wider European market. We have the business, scientific and clinical leadership to capitalise on our existing products, to bring new diagnostics into our portfolio and to develop a web-enabled bioinformatics-based product which will further enhance the potential for individualised care for HIV patients. The HIV diagnostics market in the UK is ‘mirrored’ across Europe, and negotiations are already underway to establish the business in other territories, particularly in Italy and Spain, the largest European markets.”

Mr Leaver commented on the role played by MMC Ventures and The Capital Fund:
“We are delighted that MMC Ventures and The Capital Fund are supporting a London-based company as it rolls out across Europe. As well as providing the vital capital we need to fund Delphic’s expansion, MMC Ventures and The Capital Fund have given us access to knowledgeable investors whose skills, contacts and expertise can also contribute to the company’s growth.”

Mike Kennedy, The Capital Fund’s Investment Manager, said:
“Delphic is the established market leader in UK HIV specialist diagnostics with a very competent management team who have developed a unique service offering individualised patient care. We are delighted to back the roll-out of their proven business model across Europe and wish Tim Leaver and the management team every success with their plans.”

Ben Richardson, Investment Director at MMC Ventures, said:
“We were pleased to back Delphic to roll out their cutting edge diagnostics tests to the European marketplace. The company is playing a key role in patient healthcare by providing an integrated service that will benefit the increasing number of HIV patients. Delphic is also well-placed to capitalise on similar opportunities in therapy areas suc


Publisher Contact Information:

The Capital Fund
+44 (0)1865 811199
m.henry@oxin.co.uk

Company profile of The Capital Fund
Past press releases of The Capital Fund.

Data


26,126
Tech investments
From our Online Data Service
16,881
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Sep 13N/AEnergy related
Sep 13€12.6MConsumer electronics
Sep 12€39.0MBiopharmaceuticals
Sep 12€2.3MInternet commerce
Sep 12€2.1MInternet services
Sep 12€4.0MMedical devices
Sep 12€9.0MSoftware development

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.